Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 13744-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- TRIM22 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated TRIM22 antibody (Cat. #13744-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references TRIM22 facilitates autophagosome-lysosome fusion by mediating the association of GABARAPs and PLEKHM1.
Shared biomarkers of multi-tissue origin for primary Sjogren's syndrome and their importance in immune microenvironment alterations.
Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen.
Constitutive TRIM22 Expression in the Respiratory Tract Confers a Pre-Existing Defence Against Influenza A Virus Infection.
FOXO3/TRIM22 axis abated the antitumor effect of gemcitabine in non-small cell lung cancer via autophagy induction.
TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway.
TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer.
Heo H, Park H, Lee MS, Kim J, Kim J, Jung SY, Kim SK, Lee S, Chang J
Autophagy 2024 May;20(5):1098-1113
Autophagy 2024 May;20(5):1098-1113
Shared biomarkers of multi-tissue origin for primary Sjogren's syndrome and their importance in immune microenvironment alterations.
Cai T, Xu J, Fang Y, Wu Y, Qin Q, Zhang JA
Immunobiology 2023 Sep;228(5):152726
Immunobiology 2023 Sep;228(5):152726
Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen.
Mac Kain A, Maarifi G, Aicher SM, Arhel N, Baidaliuk A, Munier S, Donati F, Vallet T, Tran QD, Hardy A, Chazal M, Porrot F, OhAinle M, Carlson-Stevermer J, Oki J, Holden K, Zimmer G, Simon-Lorière E, Bruel T, Schwartz O, van der Werf S, Jouvenet N, Nisole S, Vignuzzi M, Roesch F
Nature communications 2022 May 4;13(1):2442
Nature communications 2022 May 4;13(1):2442
Constitutive TRIM22 Expression in the Respiratory Tract Confers a Pre-Existing Defence Against Influenza A Virus Infection.
Charman M, McFarlane S, Wojtus JK, Sloan E, Dewar R, Leeming G, Al-Saadi M, Hunter L, Carroll MW, Stewart JP, Digard P, Hutchinson E, Boutell C
Frontiers in cellular and infection microbiology 2021;11:689707
Frontiers in cellular and infection microbiology 2021;11:689707
FOXO3/TRIM22 axis abated the antitumor effect of gemcitabine in non-small cell lung cancer via autophagy induction.
Wang Y, Liang HX, Zhang CM, Zou M, Zou BB, Wei W, Hu W
Translational cancer research 2020 Feb;9(2):937-948
Translational cancer research 2020 Feb;9(2):937-948
TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway.
Li L, Qi Y, Ma X, Xiong G, Wang L, Bao C
Cell biology international 2018 Sep;42(9):1192-1199
Cell biology international 2018 Sep;42(9):1192-1199
TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer.
Liu L, Zhou XM, Yang FF, Miao Y, Yin Y, Hu XJ, Hou G, Wang QY, Kang J
Oncotarget 2017 Sep 22;8(37):62069-62080
Oncotarget 2017 Sep 22;8(37):62069-62080
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The TRIM22 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human TRIM22. This antibody recognizes human, mouse antigen. The TRIM22 antibody has been validated for the following applications: ELISA, WB analysis.